Similar articles for PMID: 16740780

Year	Number of Results
1979	1
1993	1
2001	1
2002	5
2003	2
2004	8
2005	8
2006	11
2007	7
2008	16
2009	21
2010	23
2011	22
2012	17
2013	15
2014	13
2015	13
2016	11
2017	14
2018	20
2019	22
2020	19
2021	9
2022	5
2023	3
2024	0

1

Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.

Martins AS, Mackintosh C, Martín DH, Campos M, Hernández T, Ordóñez JL, de Alava E. Martins AS, et al. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40. doi: 10.1158/1078-0432.CCR-05-1778. Clin Cancer Res. 2006. PMID: 16740780

2

Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.

González I, Andreu EJ, Panizo A, Inogés S, Fontalba A, Fernández-Luna JL, Gaboli M, Sierrasesúmaga L, Martín-Algarra S, Pardo J, Prósper F, de Alava E. González I, et al. Clin Cancer Res. 2004 Jan 15;10(2):751-61. doi: 10.1158/1078-0432.ccr-0778-03. Clin Cancer Res. 2004. PMID: 14760098 Free article.

3

The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.

Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW. Warshamana-Greene GS, et al. Clin Cancer Res. 2005 Feb 15;11(4):1563-71. doi: 10.1158/1078-0432.CCR-04-1544. Clin Cancer Res. 2005. PMID: 15746061

4

The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.

Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, García-Echeverría C, Krystal GW. Warshamana-Greene GS, et al. Mol Cancer Ther. 2004 May;3(5):527-35. Mol Cancer Ther. 2004. PMID: 15141010

5

Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.

Merchant MS, Woo CW, Mackall CL, Thiele CJ. Merchant MS, et al. J Natl Cancer Inst. 2002 Nov 20;94(22):1673-9. doi: 10.1093/jnci/94.22.1673. J Natl Cancer Inst. 2002. PMID: 12441322

6

The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy.

Zhou H, Rao J, Lin J, Yin B, Sheng H, Lin F, Zhang N, Yang L. Zhou H, et al. Oncol Rep. 2011 Jun;25(6):1565-71. doi: 10.3892/or.2011.1233. Epub 2011 Mar 23. Oncol Rep. 2011. PMID: 21455580

7

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.

Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK. Tarn C, et al. Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387-92. doi: 10.1073/pnas.0803383105. Epub 2008 Jun 11. Proc Natl Acad Sci U S A. 2008. PMID: 18550829 Free PMC article.

8

A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.

Martins AS, Ordoñez JL, García-Sánchez A, Herrero D, Sevillano V, Osuna D, Mackintosh C, Caballero G, Otero AP, Poremba C, Madoz-Gúrpide J, de Alava E. Martins AS, et al. Cancer Res. 2008 Aug 1;68(15):6260-70. doi: 10.1158/0008-5472.CAN-07-3074. Cancer Res. 2008. PMID: 18676850

9

IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.

Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. Lamhamedi-Cherradi SE, et al. J Natl Cancer Inst. 2016 Aug 30;108(12):djw182. doi: 10.1093/jnci/djw182. Print 2016 Dec. J Natl Cancer Inst. 2016. PMID: 27576731 Free PMC article.

10

Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.

Loganathan SN, Tang N, Holler AE, Wang N, Wang J. Loganathan SN, et al. Mol Cancer Ther. 2019 May;18(5):929-936. doi: 10.1158/1535-7163.MCT-18-1151. Epub 2019 Mar 29. Mol Cancer Ther. 2019. PMID: 30926641 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

258 results

Results by year